BridgeMD
Exploratory study on the effect of Rimonabant on hand function in patients with spinal cord injury (RIMOHANDOPEN)
EU CTIS ID: 2025-524279-22-00
What this study is testing
To evaluate the efficacy of rimonabant in improving hand motor function in patients with cervical spinal cord injury, using the Graded Assessment of Strength, Sensation and Prehension (GRASSP) scale.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age between 18 and 75 years
- At least 2 months since spinal cord injury
- Cervical spinal cord injury (C1–C8) with AIS A–D
- Muscle strength should be within a range of 5 to 40 points on the UEMS score
- Capacity to provide informed consent
You likely can't join if
- High suicide risk assessed by C-SSRS
- Participation in another clinical trial with pharmacological intervention within the month prior to enrolment
- Any other condition that, in the opinion of the investigator, makes the subject's participation in the study unrecommended, such as severe heart failure or uncontrolled diabetes
- Contraindications for transcranial magnetic stimulation (TMS), such as metal implants in the head, pacemakers, epileptic seizures in the last two years, or other implanted electronic devices
- History of severe psychiatric disorders, major depression or prior suicide attempts
- Treatment with anticoagulants or strong CYP3A4 inhibitors or inducers
See the full eligibility criteria
- Age between 18 and 75 years
- At least 2 months since spinal cord injury
- Cervical spinal cord injury (C1–C8) with AIS A–D
- Muscle strength should be within a range of 5 to 40 points on the UEMS score
- Capacity to provide informed consent
- High suicide risk assessed by C-SSRS
- Participation in another clinical trial with pharmacological intervention within the month prior to enrolment
- Any other condition that, in the opinion of the investigator, makes the subject's participation in the study unrecommended, such as severe heart failure or uncontrolled diabetes
- Contraindications for transcranial magnetic stimulation (TMS), such as metal implants in the head, pacemakers, epileptic seizures in the last two years, or other implanted electronic devices
- History of severe psychiatric disorders, major depression or prior suicide attempts
- Treatment with anticoagulants or strong CYP3A4 inhibitors or inducers
- Body Mass Index (BMI) > 40 kg/m²
- Pregnancy or breastfeeding
- Fertile men or women who cannot guarantee the use of highly effective contraceptive methods, as defined by the European HMA-CTFG guidelines—i.e., those with a failure rate of less than 1 % per year when used consistently and correctly
- Uncontrolled hypothyroidism, or a history of severe bone, liver, or kidney disease
- Inability to attend hospital visits
- Known allergy to rimonabant or any of the excipients used
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.